Paediatric Idiopathic Myelofibrosis

Saksena, Annapurna; Arora, Prerna; Khurana, Nita; Sethi, Gulshan Rai; Singh, Tejinder

doi:10.1007/s12288-014-0412-2

Cited by 4 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The common mutations of JAK2V617F or MPLW515 K/L in adult patients with myelofibrosis are not reported in pediatric cases [ 9 ]. According to a recent study of Chinese pediatric patients with idiopathic myelofibrosis, calreticulin (CALR) mutations were detected in 50% of the cases, suggesting that CALR mutation screening could be used as a molecular marker for the diagnosis of pediatric patients with idiopathic myelofibrosis [ 10 ].…”

Section: Discussionmentioning

confidence: 99%

Non-pseudomonal Ecthyma Gangrenosum and Idiopathic Myelofibrosis in a Two-Year-Old Girl

Jamal

Rehman

2018

Cureus

View full text Add to dashboard Cite

Ecthyma gangrenosum is a skin lesion consequent to bacteremia, mostly due to Pseudomonas aeruginosa, although it may develop secondary to other organisms as well. The disease is often witnessed in patients with leukemia; however, a few cases of ecthyma gangrenosum in adults were reported to be associated with myelofibrosis. We report a case of ecthyma gangrenosum due to Escherichia coli (E. coli) in a two-year-old girl with idiopathic myelofibrosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Non-pseudomonal Ecthyma Gangrenosum and Idiopathic Myelofibrosis in a Two-Year-Old Girl

Jamal

Rehman

2018

Cureus

View full text Add to dashboard Cite

show abstract

“…У пациентов младше 21 года это заболевание встречается еще реже. В литературе описаны только 100 случаев ПМФ у детей и подростков [3].…”

unclassified

Repeated haploidentical allogeneic hematopoietic stem cell transplantation with TCR αβ/CD19 depletion in patient with primary myelofibrosis. Case report

Kolgaeva¹,

Илгаровна²,

Васильева³

et al. 2021

Terapevticheskii arkhiv

View full text Add to dashboard Cite

Indications of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with primary myelofibrosis are intermediate-2 and high-risk group of DIPSS (Dynamic International Prognostic Scoring System), beginning of the disease in childhood. The other adverse factors affect engraftment and survival after allo-HSCT, example partialy matched donor. But the result of allo-HSCT from matched related donors and result of allo-HSCT from haploidentical donors are comparable. The method for haploidentical hematopoietic stem cell transplantation is T-cell-depletion. This is clinical case of T-cell-depleted haploidentical hematopoietic stem cell transplantation in patient with primary myelofibrosis, the diagnosis was established in childhood.

show abstract